{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:59:08Z","timestamp":1791449948603,"version":"4.3.3"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T00:00:00Z","timestamp":1717632000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.esmoop.2024.103625","type":"journal-article","created":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T18:13:03Z","timestamp":1720548783000},"page":"103625","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0209-8630","authenticated-orcid":false,"given":"M.","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4259-7457","authenticated-orcid":false,"given":"M.","family":"Barve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Subbiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.P.","family":"Papadopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4349-2028","authenticated-orcid":false,"given":"D.","family":"Morgensztern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.B.","family":"Mettu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8297-3038","authenticated-orcid":false,"given":"S.","family":"Roychowdhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-2630","authenticated-orcid":false,"given":"I.","family":"Spanggaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3819-6726","authenticated-orcid":false,"given":"I.M.","family":"Silverman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gutierrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.esmoop.2024.103625_bib1","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103625_bib2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103625_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100641","article-title":"Pan-tumor landscape of fibroblast growth factor receptor 1-4 genomic alterations","volume":"7","author":"Murugesan","year":"2022","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103625_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(20)30109-1","article-title":"Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study","volume":"21","author":"Abou-Alfa","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.esmoop.2024.103625_bib5","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.annonc.2022.02.001","article-title":"FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF\/FGFR alterations and advanced malignancies","volume":"33","author":"Subbiah","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103625_bib6","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2022.40.16_suppl.3007","article-title":"Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: interim analysis (IA) results","volume":"40","author":"Loriot","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.esmoop.2024.103625_bib7","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1158\/2159-8290.CD-21-0697","article-title":"Futibatinib, an irreversible FGFR1-4 inhibitor, in patients with advanced solid tumors harboring FGF\/FGFR aberrations: a phase I dose-expansion study","volume":"12","author":"Meric-Bernstam","year":"2022","journal-title":"Cancer Discov"},{"issue":"suppl 16","key":"10.1016\/j.esmoop.2024.103625_bib8","doi-asserted-by":"crossref","first-page":"3121","DOI":"10.1200\/JCO.2023.41.16_suppl.3121","article-title":"Tumor agnostic efficacy and safety of erdafitinib (erda) in patients (pts) with advanced solid tumors with prespecified FGFR alterations (FGFRalt): RAGNAR primary analysis","volume":"41","author":"Pant","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"23","key":"10.1016\/j.esmoop.2024.103625_bib9","doi-asserted-by":"crossref","first-page":"38022","DOI":"10.18632\/oncotarget.16723","article-title":"Combination therapy in combating cancer","volume":"8","author":"Bayat","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.esmoop.2024.103625_bib10","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.ejca.2022.09.031","article-title":"Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic\u00a0review and meta-analysis","volume":"177","author":"Viscardi","year":"2022","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103625_bib11","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.3892\/ol.2020.11858","article-title":"Therapeutic implications of fibroblast growth factor receptor inhibitors in a combination regimen for solid tumors","volume":"20","author":"Luo","year":"2020","journal-title":"Oncol Lett"},{"key":"10.1016\/j.esmoop.2024.103625_bib12","series-title":"Full prescribing information","year":"2022"},{"key":"10.1016\/j.esmoop.2024.103625_bib13","series-title":"Summary of product characteristics","year":"2022"},{"key":"10.1016\/j.esmoop.2024.103625_bib14","series-title":"PEMAZYRE\u00ae (pemigatinib) product monograph. Wilmington, DE","year":"2022"},{"issue":"suppl 8","key":"10.1016\/j.esmoop.2024.103625_bib17","doi-asserted-by":"crossref","first-page":"CT016","DOI":"10.1158\/1538-7445.AM2023-CT016","article-title":"Abstract CT016: Clinical and translational findings of pemigatinib in previously treated solid tumors with activating FGFR1-3 alterations in the FIGHT-207 study","volume":"83","author":"Rodon","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103625_bib18","author":"Necchi","year":"2018"},{"issue":"7923","key":"10.1016\/j.esmoop.2024.103625_bib20","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/s41586-022-05066-5","article-title":"Truncated FGFR2 is a clinically actionable oncogene in multiple cancers","volume":"608","author":"Zingg","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.esmoop.2024.103625_bib21","year":"2022"},{"issue":"6","key":"10.1016\/j.esmoop.2024.103625_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100647","article-title":"Targeting the FGF\/FGFR axis and its co-alteration allies","volume":"7","author":"Uehara","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2024.103625_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.19.00221","article-title":"Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without FGFR alterations","volume":"3","author":"Hyman","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2024.103625_bib24","doi-asserted-by":"crossref","first-page":"S1096","DOI":"10.1016\/j.annonc.2022.07.1874","article-title":"1198TiP A phase Ib\/II open-label, nonrandomized study of FGFR inhibitor futibatinib in combination with MEK inhibitor binimetinib in patients with advanced KRAS-mutant cancer","volume":"33","author":"Rodon","year":"2022","journal-title":"Ann Oncol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103625_bib25","article-title":"Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: preliminary data from a phase 2 study","volume":"82","author":"Damodaran","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.esmoop.2024.103625_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2022.103683","article-title":"Recent therapeutic advances in urothelial carcinoma: a paradigm shift in disease management","volume":"174","author":"Bellmunt","year":"2022","journal-title":"Crit Rev Oncol Hematol"},{"issue":"suppl 4","key":"10.1016\/j.esmoop.2024.103625_bib27","doi-asserted-by":"crossref","first-page":"S586","DOI":"10.1016\/j.annonc.2020.08.829","article-title":"757P An observational study of outcomes of patients (pts) with advanced urothelial carcinoma (UC) after anti-programmed death-(ligand) 1 (PD-[L]1) therapy by fibroblast growth factor receptor gene alteration (FGFRa) status","volume":"31","author":"Rezazadeh","year":"2020","journal-title":"Ann Oncol"},{"issue":"10031","key":"10.1016\/j.esmoop.2024.103625_bib28","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"issue":"suppl 7","key":"10.1016\/j.esmoop.2024.103625_bib29","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1200\/JCO.2019.37.7_suppl.419","article-title":"Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC)","volume":"37","author":"Santiago-Walker","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.esmoop.2024.103625_bib30","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2024.103625_bib31","doi-asserted-by":"crossref","DOI":"10.1177\/11795549221126252","article-title":"Immunotherapy with checkpoint inhibitors in FGFR-altered urothelial carcinoma","volume":"16","author":"Benjamin","year":"2022","journal-title":"Clin Med Insights Oncol"},{"issue":"1","key":"10.1016\/j.esmoop.2024.103625_bib32","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12943-023-01761-7","article-title":"Unleashing the potential of combining FGFR inhibitor and immune checkpoint blockade for FGF\/FGFR signaling in tumor microenvironment","volume":"22","author":"Ruan","year":"2023","journal-title":"Mol Cancer"},{"issue":"suppl 6","key":"10.1016\/j.esmoop.2024.103625_bib33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1200\/JCO.2022.40.6_suppl.501","article-title":"Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): preliminary safety results from a phase 2 study","volume":"40","author":"Koshkin","year":"2022","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2024.103625_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2022.07.1359","article-title":"1241P Phase Ib study of futibatinib plus pembrolizumab in patients with advanced or metastatic solid tumors: tolerability results and antitumor activity in esophageal carcinoma","volume":"33","author":"Muro","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2024.103625_bib36","unstructured":"ClinicalTrials.gov. HMPL-453 (FGFR Inhibitor) in Combination With Chemotherapy or Anti-PD-1 Antibody in Advanced Solid Tumors. Available at https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05173142. Accessed January 3, 2024."}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013942?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702924013942?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T04:44:26Z","timestamp":1722401066000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702924013942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S2059702924013942"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103625","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2024.103625","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"103625"}}